1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

$Thumbnail for Artificial Intelligence, Machine Learning, and Radiomics-Based Prediction Models in Relapsed or Refractory Hodgkin Lymphoma: A Systematic Review$

HL - 1062

Artificial Intelligence, Machine Learning, and Radiomics-Based Prediction Models in Relapsed or Refractory Hodgkin Lymphoma: A Systematic Review

Sai Harsha Yendluri

Poster Presenter: Sai Harsha Yendluri

Thumbnail for ASC4FIRST Week (Wk) 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed (ND) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

CML - 1050

ASC4FIRST Week (Wk) 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed (ND) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Ghayas Issa

Poster Presenter: Ghayas Issa

Thumbnail for Asciminib (ASC) in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Analysis (IA) Efficacy and Safety Results of the Phase 2 ASC2ESCALATE Trial in the Cohort of Newly Diagnosed Patients

CML - 918

Asciminib (ASC) in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Analysis (IA) Efficacy and Safety Results of the Phase 2 ASC2ESCALATE Trial in the Cohort of Newly Diagnosed Patients

Moshe Levy

Poster Presenter: Moshe Levy

Thumbnail for Asciminib in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP): A Retrospective Chart Review Study in the US

CML - 692

Asciminib in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP): A Retrospective Chart Review Study in the US

Ehab L Atallah

Poster Presenter: Ehab L Atallah

Thumbnail for Asciminib vs Dasatinib/Nilotinib as First-Line Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: A Propensity Score-Matched Analysis of Disease Progression and Safety Outcomes

CML - 913

Asciminib vs Dasatinib/Nilotinib as First-Line Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: A Propensity Score-Matched Analysis of Disease Progression and Safety Outcomes

Ali Turunc

Poster Presenter: Ali Turunc

Thumbnail for Assessing Disparities in Outcomes After Bispecific Antibody Therapy for Hematologic Malignancies: A Single-Center Retrospective Comparison of Rural and Urban/Suburban Patients

CT - 1649

Assessing Disparities in Outcomes After Bispecific Antibody Therapy for Hematologic Malignancies: A Single-Center Retrospective Comparison of Rural and Urban/Suburban Patients

Muhammad Salman Faisal

Poster Presenter: Muhammad Salman Faisal

Thumbnail for Assessment of Awareness Regarding Look-Alike, Sound-Alike Medications (LASA) Among Healthcare Professionals: A Real Thread to Ensure Safe Medication Practices

CT - 015

Assessment of Awareness Regarding Look-Alike, Sound-Alike Medications (LASA) Among Healthcare Professionals: A Real Thread to Ensure Safe Medication Practices

Feroza Perveen

Poster Presenter: Feroza Perveen

MM - 423

Assessment of the serum level of soluble CD147 in patients with multiple myeloma

Heba Hafez

Poster Presenter: Heba Hafez

MM - 127

Association Between Statin Use and Survival in Multiple Myeloma: A Systematic Review and Meta-Analysis

Caryn Louise Gutierrez

Poster Presenter: Caryn Louise Gutierrez